Neuroprotective potential of silymarin against CNS disorders: Insight into the pathways and molecular mechanisms of action

CNS Neuroscience and Therapeutics

Volumn 19, Issue 11, 2013, Pages 847-853

  Borah, Anupom ^a   Paul, Rajib ^a   Choudhury, Sabanum ^a   Choudhury, Amarendranath ^a   Bhuyan, Bornalee ^a   Das Talukdar, Anupam ^a   Dutta Choudhury, Manabendra ^a   Mohanakumar, Kochupurackal P ^b  

^a ASSAM UNIVERSITY   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Amyloid aggregation; Antioxidant action; Astrogliosis; Estrogen receptor binding; Neuroinflammation; Oxidative and nitrosative stresses; Silymarin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LYMPHOTOXIN; MYELOPEROXIDASE; PROSTAGLANDIN SYNTHASE; SILYMARIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; DEGENERATIVE DISEASE; GLIA; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA;

AMYLOID-Β AGGREGATION; ANTIOXIDANT ACTION; ASTROGLIOSIS; ESTROGEN RECEPTOR-Β BINDING; NEUROINFLAMMATION; OXIDATIVE AND NITROSATIVE STRESSES; SILYMARIN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; SILYMARIN;

EID: 84885895884     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12175     Document Type: Review

References (86)

1. Youdim KA, Shukitt-Hale B, Joseph JA. Flavonoids and the brain: Interactions at the blood-brain barrier and their physiological effects on the central nervous system. Free Radic Biol Med 2004;37:1683-1693.
2. Pepping J. Milk thistle: Silybum marianum. Am J Health Syst Pharm 1999;56:1195-1197.
3. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139-143.
4. Luper S. A review of plants used in the treatment of liver diseases: Part 1. Altern Med Rev 1998;3:410-421.
5. Thakur SK. Silymarin - A hepatoprotective agent. Gastroenterol Today 2002;6:78-82.
6. Pradhan SC, Girish C. Hepatoprotective herbal drug, Silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491-504.
7. Das SK, Vasudevan DM. Protective effects of Silymarin, a milk thistle (Silybium marianum) derivative on ethanol-induced oxidative stress in liver. Indian J Biochem Biophys 2006;43:306-311.
8. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005;100:2583-2589.
9. Fraschini F, Dermartini G, Esposti D. Pharmacology of Silymarin. Clin Drug Invest 2002;22:51-65.
10. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: A systematic review. J Viral Hepat 2005;12:559-567.
11. Ghaffari AR, Noshad H, Ostadi A, Ghojazadeh M, Asadi P. The effects of milk thistle on hepatic fibrosis due to methotrexate in rat. Hepat Mon 2011;11:464-468.
12. Lettéron P, Labbe G, Degott C, et al. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice: Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant. Biochem Pharmacol 1990;39:2027-2034.
13. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: Past, present, future. Phytother Res 2010;24:1423-1432.
14. Wagner H, Diesel P, Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittelforschung 1974;24:466-471.
15. Rainone F. Milk thistle. Am Fam Physician 2005;72:1285-1288.
16. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: Why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007;6:110-119.
17. Gazak R, Walterova D, Kren V. Silybin and silymarin - new and emerging applications in medicine. Curr Med Chem 2007;14:315-338.
18. Ghosh A, Ghosh T, Jain S. Silymarin - a review on the pharmacodynamics and bioavailability enhancement approaches. J Pharm Sci Technol 2010;2:348-355.
19. Wagner H, Horhammer L, Munster R. On the chemistry of Silymarin (silybin) the active principle of the fruits from Silybum marianum (L.) Gaertn. (Carduus marianus L.). Arzneimittelforschung 1968;18:688-696.
20. Kim NC, Graf TN, Sparacino CM, Wani MC, Wall ME. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem 2003;1:1684-1689.
21. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod 2003;66:1171-1114.
22. Dixit N, Baboota S, Kohli K, Ahmed S, Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approach. Indian J Pharmacol 2007;39:172-179.
23. Saller R, Meier R, Brignoli R. The use of Silymarin in the treatment of liver diseases. Drugs 2001;61:2035-2063.
24. Javed S, Kohli K, Ali M. Reassessing bioavailability of Silymarin. Altern Med Rev 2011;16:239-249.
25. Song Z, Deaciuc I, Song M, et al. Silymarin protects against acute ethanol-induced hepatotoxicity in mice. Alcohol Clin Exp Res 2006;30:407-413.
26. Srivastava S, Srivastava AK, Srivastava S, Patnaik GK, Dhawan BN. Effect of picroliv and Silymarin on liver regeneration in rats. Indian J Pharmacol 1994;26:19-22.
27. Lu P, Mamiya T, Lu LL, et al. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 2009;157:1270-1277.
28. Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP. Melatonin or Silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. J Pineal Res 2011;50:97-109.
29. Raza SS, Khan MM, Ashafaq M, et al. Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: A behavioral, biochemical and immunohistological study in Wistar rats. J Neurol Sci 2011;309:45-54.
30. Galhardi F, Mesquita K, Monserrat JM, Barros DM. Effect of Silymarin on biochemical parameters of oxidative stress in aged and young rat brain. Food Chem Toxicol 2009;47:2655-2660.
31. Wang MJ, Lin WW, Chen HL, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002;16:2103-2112.
32. Wang C, Wang Z, Zhang X, et al. Protection by silibinin against experimental ischemic stroke: Up-regulated pAkt, pmTOR, HIF-1α and Bcl-2, down-regulated Bax, NF-κB expression. Neurosci Lett 2012;529:45-50.
33. Yin F, Liu J, Ji X, Wang Y, Zidichouski J, Zhang J. Silibinin: A novel inhibitor of Aβ aggregation. Neurochem Int 2011;58:399-403.
34. Baluchnejadmojarad T, Roghani M, Mafakheri M. Neuroprotective effect of Silymarin in 6-hydroxydopamine hemi-parkinsonian rat: Involvement of estrogen receptors and oxidative stress. Neurosci Lett 2010;480:206-210.
35. Lu P, Mamiya T, Lu L, et al. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav Brain Res 2010;207:387-393.
36. Lu P, Mamiya T, Lu LL, et al. Silibinin attenuates amyloid beta (25-35) peptide-induced memory impairments: Implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice. J Pharmacol Exp Ther 2009;33:319-326.
37. Hou YC, Liou KT, Chern CM, et al. Preventive effect of Silymarin in cerebral ischemia-reperfusion-induced brain injury in rats possibly through impairing NF-κB and STAT-1 activation. Phytomedicine 2010;17:963-973.
38. Murata N, Murakami K, Ozawa Y, et al. Silymarin attenuated the amyloid-β plaque burden and improved behavioral abnormalities in an Alzheimer's disease mouse model. Biosci Biotechnol Biochem 2010;74:2299-2306.
39. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: The need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001;40:959-975.
40. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009;7:65-74.
41. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26:81-104.
42. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer's disease and other neurodegenerative disorders. Ann Neurol 2011;70:532-540.
43. Schnabel J. Amyloid: Little proteins, big clues. Nature 2011;475:S12-S14.
44. Nencini C, Giorgi G, Micheli L. Protective effect of Silymarin on oxidative stress in rat brain. Phytomedicine 2007;14:129-135.
45. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57-87.
46. Borah A, Mohanakumar KP. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 2007;27:985-996.
47. Borah A, Mohanakumar KP. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res 2009;47:293-300.
48. Borah A, Mohanakumar KP. Long term L-DOPA treatment causes production of 6-OHDA in the mouse striatum: Involvement of hydroxyl radical. Ann Neurosci 2009;16:160-165.
49. Borah A, Mohanakumar KP. L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochem Int 2010;56:352-362.
50. Borah A, Mohanakumar KP. Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism. Brain Res 2010;16:192-199.
51. Borah A, Mohanakumar KP. L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients. Med Hypotheses 2012;79:271-273.
52. Osuchowski MF, Johnson VJ, He Q, Sharma RP. Alterations in regional brain neurotransmitters by silymarin, a natural antioxidant flavonoid mixture, in BALB/c mice. Pharmac Biol 2004;42:384-389.
53. Mazzio EA, Harris N, Soliman KF. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med 1998;64:603-606.
54. Robottom BJ. Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. Patient Prefer Adherence 2011;5:57-64.
55. Riederer P, Laux G. MAO-inhibitors in Parkinson's disease. Exp Neurol 2011;20:1-17.
56. Lee VM-Y, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological α-synuclein: New targets for drug discovery. Neuron 2006;52:33-38.
57. Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 2012;18:S207-S209.
58. Bemeur C, Ste-Marie L, Montgomery J. Increased oxidative stress during hyperglycemic cerebral ischemia. Neurochem Int 2007;50:890-904.
59. Rodrigo J, Fernández AP, Serrano J, Peinado MA, Martínez A. The role of free radicals in cerebral hypoxia and ischemia. Free Radic Biol Med 2005;39:26-50.
60. Ozkul A, Akyol A, Yenisey C, Arpaci E, Kiylioglu N, Tataroglu C. Oxidative stress in acute ischemic stroke. J Clin Neurosci 2007;14:1062-1066.
61. Muley MM, Thakare VN, Patil RR, Kshirsagar AD, Naik SR. Silymarin improves the behavioural, biochemical and histoarchitecture alterations in focal ischemic rats: A comparative evaluation with piracetam and protocatachuic acid. Pharmacol Biochem Behav 2012;102:286-293.
62. Chtourou Y, Fetoui H, Garoui el M, Boudawara T, Zeghal N. Improvement of cerebellum redox states and cholinergic functions contribute to the beneficial effects of Silymarin against manganese-induced neurotoxicity. Neurochem Res 2012;37:469-479.
63. Chtourou Y, Fetoui H, Sefi M, et al. Silymarin, a natural antioxidant, protects cerebral cortex against manganese-induced neurotoxicity in adult rats. Biometals 2010;23:985-996.
64. Toklu HZ, Tunali Akbay T, Velioglu-Ogunc A, et al. Silymarin, the antioxidant component of Silybum marianum, prevents sepsis-induced acute lung and brain injury. J Surg Res 2008;145:214-222.
65. Vengerovskii AI, Khazanov VA, Eskina KA, Vasilyev KY. Effects of Silymarin (hepatoprotector) and succinic acid (bioenergy regulator) on metabolic disorders in experimental diabetes mellitus. Bull Exp Biol Med 2007;144:53-56.
66. Schubert D, Behl C, Lesley R, et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U S A 1995;92:1989-1993.
67. Pappolla MA, Chyan YJ, Omar RA, et al. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: A chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998;152:871-877.
68. Ishii K, Muelhauser F, Liebl U, et al. Sub-acute NO generation induced by Alzheimer's beta-amyloid in the living brain: Reversal by inhibition of the inducible NO synthase. FASEB J 2000;14:1485-1489.
69. Tran MH, Yamada K, Nakajima A, et al. Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction. Mol Psychiatry 2003;8:407-412.
70. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-741.
71. Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000;290:150-153.
72. Tsai MJ, Liao JF, Lin DY, et al. Silymarin protects spinal cord and cortical cells against oxidative stress and lipopolysaccharide stimulation. Neurochem Int 2010;57:867-875.
73. Posner MI, Petersen SE, Fox PT, Raichle ME. Localization of cognitive operations in the human brain. Science 1988;240:1627-1631.
74. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 1997;388:507-525.
75. Seidlova-Wuttke D, Becker T, Christoffel V, Jarry H, Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J Steroid Biochem Mol Biol 2003;86:179-188.
76. El-Shitany NA, Hegazy S, El-desoky K. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of Silymarin compared with ethinylestradiol in ovariectomized rats. Phytomedicine 2010;17:116-125.
77. Rissman EF, Heck AL, Leonard JE, Shupnik MA, Gustafsson JA. Disruption of estrogen receptor beta gene impairs spatial learning in female mice. Proc Natl Acad Sci U S A 2002;99:3996-4001.
78. Swedenborg E, Power KA, Cai W, Pongratz I, Ruegg J. Regulation of estrogen receptor beta activity and implications in health and disease. Cell Mol Life Sci 2009;66:3873-3894.
79. Hughes ZA, Liu F, Marquis K, et al. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol 2009;2:215-236.
80. Hill RA, Boon WC. Estrogens, brain, and behavior: Lessons from knockout mouse models. Semin Reprod Med 2009;27:218-228.
81. Chung SJ, Armasu SM, Biernacka JM, et al. Variants in estrogen-related genes and risk of Parkinson's disease. Mov Disord 2011;26:1234-1242.
82. Zhao L, Wu TW, Brinton RD. Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Brain Res 2004;1010:22-34.
83. Kummer V, Maskova J, Canderle J, Zraly Z, Neca J, Machala NM. Estrogenic effects of Silymarin in ovariectomized rats. Vet Med (Praha) 2001;46:17-23.
84. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 2005;239:27-36.
85. Pliskova M, Vondrácek J, Kren V, et al. Effects of Silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 2005;215:80-89.
86. Wang Q, Zou L, Liu W, et al. Inhibiting NF-κB activation and ROS production are involved in the mechanism of silibinin's protection against D-galactose-induced senescence. Pharmacol Biochem Behav 2011;98:140-149.